ERCC1表达水平与晚期食管癌患者含奈达铂方案化疗疗效的相关性  

The clinical research of ERCC1 expression in advanced esophageal cancer treated with nedaplantin chemotherapy

作　　者：李笑秋[1] 胡冰[1] 王刚[1] 季楚舒[1] 江丰收[1] 王勇[1] 孙玉蓓[1] 姚艺玮 

机构地区：[1]安徽医科大学附属省立医院肿瘤科,合肥230001

出　　处：《安徽医科大学学报》2010年第6期789-791,共3页Acta Universitatis Medicinalis Anhui

基　　金：安徽省自然科学基金(编号:070413256X)

摘　　要：目的探讨晚期食管癌患者组织中切除修复交叉互补基因1(ERCC1)与含奈达铂联合化疗疗效的关系。方法回顾性研究84例晚期食管癌患者病理组织中ERCC1基因表达。所有患者均接受含奈达铂的联合化疗,观察疾病控制率与ERCC1表达之间的关系。结果 84例患者ERCC1表达阳性率为88.1%(74/84),总疾病控制率为36.9%(31/84),其中ERCC1表达阴性组的疾病控制率优于表达阳性组,差异有统计学意义(χ2=9.054,P=0.004)。结论晚期食管癌病理组织中ERCC1基因表达对于接受含奈达铂联合化疗疗效预测有指导作用。Objective To investigate the relationship between ERCC1 expression in advanced esophageal cancer and the chemotherapy effect treated with nedaplatin.Methods 84 pathological specimens of advanced esophageal cancer patients were collected to detect ERCC1 expression.All patients received nedaplatin chemotherapy.We analyzed the relationship between ERCC1 expression in advanced esophageal carcinoma and disease control response （DCR） .Results In all 84 patients,the positive rate of ERCC1 expression was 88.1%（74/84） ,the overall disease control rate was 36.9% （31 /84） ,while overall disease control rate in negative group of ERCC1 expression was higher than that in positive group,which showed statistical difference（χ2 = 9.054,P = 0.004） .Conclusion ERCC1 expression in advanced esophageal cancer is a promising index to predict clinical outcome treated with nedaplatin chemotherapy.

关 键 词：食管肿瘤 癌 鳞状细胞 免疫组织化学 

分 类 号：R735.1[医药卫生—肿瘤] R394[医药卫生—临床医学]